
Simulations Plus, Inc.
HealthcareNASDAQ:SLP · NASDAQ Global Select
-$0.17 today
Vol 0.16M · Avg 0.33M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$80.5M of revenue converted into -$62.8M of net income for the selected period. Gross margin is 61.5% and net margin is -78.0%, showing how much revenue survives after costs and taxes. EPS is $-3.13, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.2M +13.1% | $70.0M +17.5% | $59.6M +10.5% | $53.9M +16.0% | $46.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $33.0M +22.7% | $26.9M +131.0% | $11.6M +7.5% | $10.8M +2.1% | $10.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $46.2M +7.1% | $43.2M -10.0% | $47.9M +11.3% | $43.1M +20.1% | $35.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 58.4% -3.3pp | 61.6% -18.8pp | 80.5% +0.6pp | 79.9% +2.7pp | 77.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $6.9M +19.6% | $5.8M +27.8% | $4.5M +40.4% | $3.2M -20.7% | $4.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $32.8M +5.1% | $31.3M -9.9% | $34.7M +39.1% | $25.0M +21.4% | $20.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $117.0M +215.9% | $37.0M -5.6% | $39.2M +39.2% | $28.2M +14.5% | $24.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $8.2M +44.9% | $5.7M +47.5% | $3.8M +7.4% | $3.6M -0.4% | $3.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $14.7M -18.7% | $18.1M +38.4% | $13.1M -30.1% | $18.7M +27.2% | $14.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 18.6% -7.2pp | 25.8% +3.9pp | 21.9% -12.7pp | 34.7% +3.0pp | 31.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$70.7M -1253.6% | $6.1M -29.7% | $8.7M -41.5% | $14.9M +32.5% | $11.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -89.3% -98.1pp | 8.8% -5.9pp | 14.6% -13.0pp | 27.7% +3.4pp | 24.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $722.0K -83.5% | $4.4M +5.9% | $4.1M +476.2% | $717.0K +256.7% | $201.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 -100.0% | $22.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.4M -78.5% | $6.3M +111.4% | $3.0M +1355.9% | $204.0K +221.4% | -$168.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$69.4M -659.0% | $12.4M +6.1% | $11.7M -22.6% | $15.1M +36.4% | $11.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -87.6% -105.3pp | 17.7% -1.9pp | 19.6% -8.4pp | 28.0% +4.2pp | 23.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$4.7M -289.6% | $2.5M +41.7% | $1.7M -34.1% | $2.6M +102.0% | $1.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$64.7M -750.2% | $10.0M -0.1% | $10.0M -20.2% | $12.5M +27.6% | $9.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -81.7% -96.0pp | 14.2% -2.5pp | 16.7% -6.4pp | 23.2% +2.1pp | 21.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -744.0% | $1 +0.0% | $1 -19.4% | $1 +26.5% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -757.1% | $0 +0.0% | $0 -18.3% | $1 +27.7% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $20.1M +0.6% | $20.0M -0.4% | $20.1M -0.6% | $20.2M +0.8% | $20.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $20.1M -1.0% | $20.3M -0.8% | $20.5M -1.4% | $20.7M +0.0% | $20.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

Agilon Health, Inc.
NYSE:AGL
$1.88B

Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M

National Research Corporation
NASDAQ:NRC
$423.46M

SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M

Cellectis S.A.
NASDAQ:CLLS
$310.29M

AC Immune S.A.
NASDAQ:ACIU
$235.10M

Korro Bio, Inc.
NASDAQ:KRRO
$115.56M

OptimizeRx Corporation
NASDAQ:OPRX
$98.14M

Definitive Healthcare Corp.
NASDAQ:DH
$88.59M

Nakamoto Inc.
NASDAQ:NAKA
$75.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SLP generate?
Simulations Plus, Inc. (SLP) reported $79.18M of revenue in fiscal 2025.
Is SLP profitable?
Simulations Plus, Inc. (SLP) reported -$64,718,000.00 of net income, with a net margin of -81.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.